Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T. Annals of internal medicine review meta-analysis : diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146:797–808.CrossrefPubMedGoogle Scholar
Cambridge G, Acharya J, Cooper JA, Edwards JC, Humphries SE. Antibodies to citrullinated peptides and risk of coronary heart disease. Atherosclerosis 2013;228:243–6.PubMedCrossrefWeb of ScienceGoogle Scholar
Hwang SM, Kim JO, Yoo YM, Shin S, Kim JQ, Park MH, et al. Performance analysis of the ARCHITECT anti-cyclic citrullinated peptide antibody in the diagnosis of rheumatoid arthritis. Clin Chem Lab Med 2010;48:225–30.Web of ScienceGoogle Scholar
Hermans MP, van der Velden D, Montero Cabezas JM, Putter H, Huizinga TW, Kuiper J, et al. Long-term mortality in patients with ST-segment elevation myocardial infarction is associated with anti-citrullinated protein antibodies. Int J Cardiol 2017;240:20–4.CrossrefWeb of SciencePubMedGoogle Scholar
Online erschienen: 09.11.2018
Erschienen im Druck: 26.06.2019
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and have approved submission.
Research funding: This work was supported by the Kerckhoff Heart Research Institute together with the Justus Liebig University (KHFI). The BioProspective study cohort was funded by the German Centre for Cardiovascular Research (DZHK) and the William G. Kerckhoff Stiftung, Bad Nauheim, Germany.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.